
Follow WOWNEWS 24x7 on:
Updated: July 09, 2025 15:24
Indo US Bio-Tech Ltd has signed a Memorandum of Understanding with the Indian Agricultural Research Institute (ICAR-IARI) to produce and commercialise the maize hybrid HQPM-5. The collaboration marks a significant step in strengthening India’s seed innovation ecosystem and enhancing maize productivity through public-private partnerships.
Key Highlights From the MoU
- The agreement enables Indo US Bio-Tech to produce, market, and distribute the HQPM-5 maize hybrid developed by ICAR-IARI
- HQPM-5 is a high-quality protein maize variety known for improved nutritional content and yield performance
- The partnership aims to expand access to superior maize genetics for Indian farmers, especially in rainfed and semi-arid regions
- The MoU reflects ICAR-IARI’s strategy to scale its research outputs through industry collaboration
- Indo US Bio-Tech will leverage its pan-India distribution network and seed processing infrastructure to ensure timely availability
Strategic Context and Industry Impact
- The maize hybrid HQPM-5 is designed to address protein deficiency in staple diets, offering better lysine and tryptophan content
- The collaboration supports India’s national goals of nutritional security and sustainable agriculture
- Indo US Bio-Tech has previously partnered with ICAR and other institutions for hybrid seed development across crops like rice, cotton, and vegetables
- The move aligns with the company’s mission to deliver climate-resilient, high-yielding seed varieties to smallholder farmers
Sources: BSE India, Indo US Bio-Tech Ltd regulatory filings, ICAR-IARI official site, Economic Times Markets, Indian Seed Industry Tracker, Moneycontrol SME Desk